XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3
Debt - Liability for Sale of Future Royalties (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2024
USD ($)
Debt Disclosure [Abstract]  
Beginning balance $ 1,814,097
Less: Non-cash royalty revenue payable to Royalty Pharma (128,877)
Plus: non-cash interest expense recognized 155,039
Cash received from Royalty Pharma 241,792
Ending balance $ 2,082,051
Effective interest rate of the liability component 9.90%